Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-021705
Filing Date
2025-02-14
Accepted
2025-02-14 20:36:50
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9235
2 EX-99.A ck0001669811-ex99_a.pdf EX-99.A 49649
  Complete submission text file 0000950170-25-021705.txt   79466
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Subject) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-42217 | Film No.: 25632166
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address
Business Address
HALPERN JOHN D (Filed by) CIK: 0001234950 (see all company filings)

Type: SCHEDULE 13G/A